James A Triccas

List of Publications by Year
in descending order

101 papers	7,259 citations	126907 33 h-index	71685 76 g-index
115 all docs	115 docs citations	115 times ranked	11453 citing authors

#	Article	IF	Citations
1	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	30.7	3,133
2	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	7.3	436
3	Analysis of the Phthiocerol Dimycocerosate Locus ofMycobacterium tuberculosis. Journal of Biological Chemistry, 2001, 276, 19845-19854.	3.4	335
4	Cutaneous immunosurveillance by self-renewing dermal Î³Î´ T cells. Journal of Experimental Medicine, 2011, 208, 505-518.	8.5	248
5	Migratory Dermal Dendritic Cells Act as Rapid Sensors of Protozoan Parasites. PLoS Pathogens, 2008, 4, e1000222.	4.7	213
6	An inducible expression system permitting the efficient purification of a recombinant antigen fromMycobacterium smegmatis. FEMS Microbiology Letters, 1998, 167, 151-156.	1.8	132
7	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	22.7	93
8	Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis, 2010, 90, 354-360.	1.9	92
9	BCG vaccination against tuberculosis: past disappointments and future hopes. Trends in Microbiology, 1995, 3, 397-401.	7.7	85
10	Differential T Cell Responses To Mycobacteria-Secreted Proteins Distinguish Vaccination With Bacille Calmette-Guerin From Infection With Mycobacterium Tuberculosis. Journal of Infectious Diseases, 1994, 170, 1326-1330.	4.0	78
11	Expression of Mycobacterium tuberculosis MPT64 in recombinant Myco. smegmatis : purification, immunogenicity and application to skin tests for tuberculosis. Clinical and Experimental Immunology, 1996, 103, 226-232.	2.6	77
12	The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. Microbiology (United Kingdom), 2004, 150, 1681-1686.	1.8	75
13	New tuberculosis drug leads from naturally occurring compounds. International Journal of Infectious Diseases, 2017, 56, 212-220.	3.3	72
14	Plasmid Interleukin-23 (IL-23), but Not Plasmid IL-27, Enhances the Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection. Infection and Immunity, 2006, 74, 557-565.	2.2	71
15	Use of fluorescence induction and sucrose counterselection to identify Mycobacterium tuberculosis genes expressed within host cells. Microbiology (United Kingdom), 1999, 145, 2923-2930.	1.8	68
16	Recombinant Mycobacterium bovis bacillus Calmette-GuÃ©rin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clinical and Experimental Immunology, 2004, 137, 24-34.	2.6	66
17	Antigen Load Governs the Differential Priming of CD8 T Cells in Response to the Bacille Calmette Guerin Vaccine or Mycobacterium tuberculosis Infection. Journal of Immunology, 2009, 182, 7172-7177.	0.8	66
18	Characterization of the gene encoding the immunodominant 35 kDa protein of Mycobacterium leprae. Molecular Microbiology, 1995, 16, 865-876.	2.5	58

#	Article	IF	Citations
19	Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection. Scientific Reports, 2017, 7, 8582.	3.3	57
20	Functional Interplay between Type I and II Interferons Is Essential to Limit Influenza A Virus-Induced Tissue Inflammation. PLoS Pathogens, 2016, 12, e1005378.	4.7	54
21	Modulation of pulmonary DC function by vaccineâ€encoded GMâ€CSF enhances protective immunity against Mycobacterium tuberculosis infection. European Journal of Immunology, 2010, 40, 153-161.	2.9	50
22	Coexpression of Interleukin-12 Chains by a Self-Splicing Vector Increases the Protective Cellular Immune Response of DNA and Mycobacterium bovis BCG Vaccines against Mycobacterium tuberculosis. Infection and Immunity, 2002, 70, 1949-1956.	2.2	49
23	A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans. Nature Communications, 2018, 9, 85.	12.8	49
24	Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4+ memory T cells that are associated with protection against tuberculosis. Mucosal Immunology, 2018, 11, 1743-1752.	6.0	48
25	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. ACS Central Science, 2021, 7, 1001-1008.	11.3	47
26	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. Npj Vaccines, 2021, 6, 143.	6.0	47
27	Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. Journal of Hepatology, 2012, 57, 352-358.	3.7	46
28	Protective immunity afforded by attenuated, PhoPâ€deficient Mycobacterium tuberculosis is associated with sustained generation of CD4⁺ Tâ€cell memory. European Journal of Immunology, 2012, 42, 385-392.	2.9	46
29	Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. Npj Vaccines, 2020, 5, 105.	6.0	45
30	Mycobacterium tuberculosisDefective in Phthiocerol Dimycocerosate Translocation Provides Greater Protective Immunity against Tuberculosis than the Existing Bacille Calmetteâ€GuÃ©rin Vaccine. Journal of Infectious Diseases, 2004, 189, 105-112.	4.0	44
31	Nontoxic Metalâ€“Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2016, 59, 5917-5921.	6.4	42
32	Improved Protection against Disseminated Tuberculosis byMycobacterium bovisBacillus Calmette-GuÃ©rin Secreting Murine GM-CSF Is Associated with Expansion and Activation of APCs. Journal of Immunology, 2007, 179, 8418-8424.	0.8	41
33	Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine, 2005, 23, 1680-1685.	3.8	37
34	Comparative affects of plasmidâ€encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunology and Cell Biology, 2002, 80, 346-350.	2.3	34
35	Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 2014, 85, 269-278.	2.3	33
36	Antitubercular Bis-Substituted Cyclam Derivatives: Structureâ€“Activity Relationships and in Vivo Studies. Journal of Medicinal Chemistry, 2018, 61, 3595-3608.	6.4	33

#	Article	IF	Citations
37	Molecular and Immunological Analyses of the Mycobacterium avium Homolog of the Immunodominant Mycobacterium leprae 35-Kilodalton Protein. Infection and Immunity, 1998, 66, 2684-2690.	2.2	33
38	Protection against Virulent Mycobacterium avium Infection following DNA Vaccination with the 35-Kilodalton Antigen Is Accompanied by Induction of Gamma Interferon-Secreting CD4 + T Cells. Infection and Immunity, 2000, 68, 3090-3096.	2.2	31
39	Effects of DNA- and Mycobacterium bovis BCG-Based Delivery of the Flt3 Ligand on Protective Immunity to Mycobacterium tuberculosis. Infection and Immunity, 2007, 75, 5368-5375.	2.2	30
40	The Secreted Lipoprotein, MPT83, of Mycobacterium tuberculosis Is Recognized during Human Tuberculosis and Stimulates Protective Immunity in Mice. PLoS ONE, 2012, 7, e34991.	2.5	30
41	Influenza A Virus Infection Impairs Mycobacteria-Specific T Cell Responses and Mycobacterial Clearance in the Lung during Pulmonary Coinfection. Journal of Immunology, 2013, 191, 302-311.	0.8	29
42	Epitopeâ€specific CD4⁺, but not CD8⁺, Tâ€cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. European Journal of Immunology, 2015, 45, 780-793.	2.9	28
43	Organometallic Conjugates of the Drug Sulfadoxine for Combatting Antimicrobial Resistance. Chemistry - A European Journal, 2018, 24, 10078-10090.	3.3	28
44	Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms, 2019, 7, 255.	3.6	28
45	The Trifunctional Sulfate-activating Complex (SAC) of Mycobacterium tuberculosis. Journal of Biological Chemistry, 2005, 280, 7861-7866.	3.4	27
46	Harnessing Single Cell Sorting to Identify Cell Division Genes and Regulators in Bacteria. PLoS ONE, 2013, 8, e60964.	2.5	27
47	A novel levansucraseâ€“levanase gene cluster in Bacillus stearothermophilus ATCC12980. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1353, 203-208.	2.4	24
48	Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. Npj Vaccines, 2016, 1, 16012.	6.0	24
49	Life on the inside: Probing Mycobacterium tuberculosis gene expression during infection. Immunology and Cell Biology, 2000, 78, 311-317.	2.3	23
50	The generation of Tâ€cell memory to protect against tuberculosis. Immunology and Cell Biology, 2019, 97, 656-663.	2.3	23
51	Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish. Nature Communications, 2022, 13, 952.	12.8	23
52	Deciphering protective immunity against tuberculosis: implications for vaccine development. Expert Review of Vaccines, 2019, 18, 353-364.	4.4	22
53	Neuroprotective peptideâ€“macrocycle conjugates reveal complex structureâ€“activity relationships in their interactions with amyloid Î². Metallomics, 2014, 6, 1931-1940.	2.4	20
54	Isolation of strong expression signals of Mycobacterium tuberculosis. Microbiology (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td	1.8	20

#	Article	IF	Citations
55	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Clinical Infectious Diseases, 2022, 75, e878-e879.	5.8	20
56	In vivo persistence and protective efficacy of the Bacille Calmette GuÃ©rin vaccine overexpressing the HspX latency antigen. Bioengineered Bugs, 2010, 1, 61-65.	1.7	19
57	Modulation of gene expression by Pseudomonas aeruginosa during chronic infection in the adult cystic fibrosis lung. Microbiology (United Kingdom), 2013, 159, 2354-2363.	1.8	19
58	Structureâ€“Activity Relationships of cyclo(<scp>l</scp>-Tyrosyl-<scp>l</scp>-tyrosine) Derivatives Binding to Mycobacterium tuberculosis CYP121: Iodinated Analogues Promote Shift to High-Spin Adduct. Journal of Medicinal Chemistry, 2019, 62, 9792-9805.	6.4	19
59	Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria. Plasmid, 2005, 53, 269-273.	1.4	17
60	Secretion of Functional Monocyte Chemotactic Protein 3 by Recombinant Mycobacterium bovis BCG Attenuates Vaccine Virulence and Maintains Protective Efficacy against M. tuberculosis Infection. Infection and Immunity, 2007, 75, 523-526.	2.2	17
61	Destabilized green fluorescent protein for monitoring transient changes inÂmycobacterial gene expression. Research in Microbiology, 2002, 153, 379-383.	2.1	16
62	Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine, 2010, 28, 1341-1346.	3.8	16
63	Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis. Vaccine, 2018, 36, 2619-2629.	3.8	16
64	Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery. Pharmaceutics, 2019, 11, 555.	4.5	16
65	Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG. Vaccine, 2011, 29, 1374-1381.	3.8	14
66	The Ag85B protein of the BCG vaccine facilitates macrophage uptake but is dispensable for protection against aerosol Mycobacterium tuberculosis infection. Vaccine, 2016, 34, 2608-2615.	3.8	14
67	Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens. European Journal of Medicinal Chemistry, 2018, 148, 507-518.	5.5	14
68	Specific Serological Diagnosis of Leprosy with a Recombinant Mycobacterium leprae Protein Purified from a Rapidly Growing Mycobacterial Host. Journal of Clinical Microbiology, 1998, 36, 2363-2365.	3.9	14
69	Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science. PLoS ONE, 2014, 9, e111782.	2.5	14
70	Analysis of stress- and host cell-induced expression of the Mycobacterium tuberculosis inorganic pyrophosphatase. BMC Microbiology, 2001, 1, 3.	3.3	13
71	Identification of strong promoter elements ofMycobacterium smegmatisand their utility for foreign gene expression in mycobacteria. FEMS Microbiology Letters, 2003, 224, 139-142.	1.8	13
72	Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioengineered Bugs, 2010, 1, 110-115.	1.7	12

#	Article	IF	Citations
73	Host Cellâ€“Induced Components of the Sulfate Assimilation Pathway Are Major Protective Antigens of Mycobacterium tuberculosis. Journal of Infectious Diseases, 2013, 207, 778-785.	4.0	12
74	Incorporation of Bulky and Cationic Cyclamâ€Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen, 2013, 2, 99-105.	1.9	12
75	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 523.	3.7	12
76	The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses. Immunology Letters, 2010, 130, 36-42.	2.5	11
77	Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis. Vaccine, 2011, 29, 7759-7765.	3.8	11
78	Novel vaccination approaches to prevent tuberculosis in children. Pneumonia (Nathan Qld), 2016, 8, 18.	6.1	11
79	Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis. Scientific Reports, 2019, 9, 14396.	3.3	10
80	Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics. Frontiers in Immunology, 2021, 12, 740117.	4.8	10
81	Pseudomonas aeruginosa strains from the chronically infected cystic fibrosis lung display increased invasiveness of A549 epithelial cells over time. Microbial Pathogenesis, 2012, 53, 37-43.	2.9	9
82	Virulence Mechanisms of Mycobacterium abscessus: Current Knowledge and Implications for Vaccine Design. Frontiers in Microbiology, 2022, 13, 842017.	3.5	9
83	Challenge of developing new tuberculosis vaccines to generate life-long protective immunity. Expert Review of Vaccines, 2009, 8, 823-825.	4.4	8
84	Non-classical Î²-carbonic anhydrase inhibitors-towards novel anti-mycobacterials. MedChemComm, 2014, 5, 1563-1566.	3.4	8
85	Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. Mucosal Immunology, 2021, 14, 762-773.	6.0	8
86	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	3.0	8
87	Homogentisate 1-2-Dioxygenase Downregulation in the Chronic Persistence of Pseudomonas aeruginosa Australian Epidemic Strain-1 in the CF Lung. PLoS ONE, 2015, 10, e0134229.	2.5	7
88	Contribution of <scp>L</scp>â€Alanine Dehydrogenase to In Vivo Persistence and Protective Efficacy of the BCG Vaccine. Microbiology and Immunology, 2006, 50, 805-810.	1.4	5
89	Infectious diseases: Too little, too late for tuberculosis. Immunology and Cell Biology, 2008, 86, 293-294.	2.3	5
90	Heterologous Expression of Genes in Mycobacteria. Methods in Molecular Biology, 2009, 465, 243-253.	0.9	5

#	Article	IF	Citations
91	Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit. RSC Medicinal Chemistry, 2021, 12, 943-959.	3.9	5
92	TCR Affinity Controls the Dynamics but Not the Functional Specification of the Antimycobacterial CD4+ T Cell Response. Journal of Immunology, 2021, 206, 2875-2887.	0.8	5
93	An inducible expression system for high-level expression of recombinant proteins in slow growing mycobacteria. Plasmid, 2015, 81, 27-31.	1.4	4
94	Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine, 2021, 39, 1990-1996.	3.8	4
95	Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. PLoS ONE, 2021, 16, e0259829.	2.5	3
96	Characterization of the Protective Immune Responses Conferred by Recombinant BCG Overexpressing Components of Mycobacterium tuberculosis Sec Protein Export System. Vaccines, 2022, 10, 945.	4.4	3
97	Development and delivery of anti-tuberculosis drugs, vaccines and immunotherapeutics. Advanced Drug Delivery Reviews, 2016, 102, 1-2.	13.7	2
98	The Constituents of the Cell Envelope and Their Impact on the Host Immune System. , 0, , 249-270.		2
99	Influence of phthiocerol dimycocerosate on CD4+ T cell priming and persistence during Mycobacterium tuberculosis infection. Tuberculosis, 2016, 99, 25-30.	1.9	1
100	Immunity toMycobacterium tuberculosis. Clinical and Developmental Immunology, 2011, 2011, 1-2.	3.3	0
101	Frontispiece: Organometallic Conjugates of the Drug Sulfadoxine for Combatting Antimicrobial Resistance. Chemistry - A European Journal, 2018, 24, .	3.3	0